Apogee secures Blackstone capital to move Dupixent rival into Phase 3
The biggest question Apogee Therapeutics CEO Michael Henderson gets from investors? "These are big markets, this takes a lot of capital — are you just going to...
The biggest question Apogee Therapeutics CEO Michael Henderson gets from investors? "These are big markets, this takes a lot of capital — are you just going to dilute us every time you have data?" Henderson said ...